Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SABS
SAB BIOTHERAPEUTICS, INC.
NASDAQ
$3.79
▼ DOWN 3.56% (-0.14)

KEY STATISTICS

Market Cap$344.84 M
52w High$5.15
52w Low$1.85
Dividend Yield—
Frequency—
P/E-2.92
Volume202.59K
Shares Out.90.99M

COMPANY

LEADERSHIP

Samuel J. Reich
CHIEF EXECUTIVE
Samuel J. Reich

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 9, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
86

PRICE TARGET

Target High$13.00
Target Low$10.00
Target Median$11.00
Target Consensus$11.33

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.$125.00K
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2024-01-05Reverse1:10

PRICE

$3.79 ▼ DOWN 3.56% (−$0.14)
OVERLAYS
$3.80$3.85$3.90$3.959:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.79

About SAB Biotherapeutics, Inc.

https://www.sab.bio ↗

SAB Biotherapeutics develops human antibody-based immunotherapies using genetically engineered cattle, with lead candidates like SAB-185 for COVID-19 and SAB-176 for influenza, targeting infectious and autoimmune diseases.

INDUSTRY

Biotechnology

A PRODUCT SAB BIOTHERAPEUTICS, INC. IS KNOWN FOR

SAB-142
SAB-142

SAB-142 is a clinical-stage, fully human anti-thymocyte immunoglobulin in Phase 2b trials, aiming to delay and modify Stage 3 Type 1 Diabetes by preserving insulin-producing beta cells.

COMPETITORS

COMPETITOR
ELDN COMPARE
KYTX COMPARE
MGNX COMPARE
NKTR COMPARE
RIGL COMPARE

Revenue by Products

IconPRODUCTQ1-2022Q2-2022Q3-2022
Grant Revenue$11.8M $6.35M ▼$3.59M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
44
LISTED HERE
10
RANKED BY POSITION SIZE
VTS.AX
0.00% · 2.3M
IWM
0.00% · 1.0M
AVSC
0.01% · 107.1K
SURI
0.46% · 104.8K
SBIO
0.15% · 94.6K
GSSC
0.02% · 54.2K
XRS2.F
0.01% · 39.7K
RSSL
0.01% · 20.6K
URTY
0.00% · 1.8K
RTYS.L
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
59.20%
HOLDERS
88
TOP 12 OF 88 · RANKED BY POSITION SIZE
Vivo Capital, LLC
11.4M sh · $43.74M
Caligan Partners LP
8.0M sh · $30.51M
Perceptive Advisors LLC
6.4M sh · $24.63M
Ra Capital Management, L.P.
4.4M sh · $16.86M
Commodore Capital LP
4.4M sh · $16.86M
Balyasny Asset Management L.P.
3.8M sh · $14.4M
Adage Capital Partners Gp, L.L.C.
3.4M sh · $13.04M
Millennium Management LLC
3.0M sh · $11.62M
Woodline Partners LP
2.9M sh · $10.92M
Sessa Capital Im, L.P.
2.2M sh · $8.22M
Blackstone Inc.
2.1M sh · $8.02M
Vanguard Group Inc
1.8M sh · $6.91M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings3
Price To Book4
Overall Score3

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Kropotova Alexandra
Sale · 988 shares
2026-06-25
★
OFFICER: CHIEF MEDICAL OFFICER
Kropotova Alexandra
Sale · 988 shares
2026-03-24
★
OFFICER: SEE REMARKS
To Lucy
Purchase · 2.4M shares
2026-02-03
★
DIRECTOR, OFFICER: PRESIDENT
Sullivan Eddie Joe
Purchase · 3.0M shares
2026-02-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
Chardan Capital BUY HC Wainwright & Co. BUY Leerink Partners OUTPERFORM Rodman & Renshaw BUY

SECTORS PEERS

PEERPRICE
QTTB$15.03COMPARE
ANTX$5.58COMPARE
VRCA$5.69COMPARE
BOLD$2.83COMPARE
NXTC$6.09COMPARE
EVAX$3.01COMPARE
PLUR$1.53COMPARE
JSPR$0.70COMPARE